Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11914194 | 0.91 | ALDH1A1 (0.38) | ALDH1A1KDM4EGAACYP1A1CYP1B1 | |
| SCHEMBL2491707 | 0.89 | PDE4A (0.40) | ALDH1A1KDM4ECYP1A1CYP1B1CYP3A4 | |
| SCHEMBL15171996 | 0.89 | CYP3A4 (0.35) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL15171999 | 0.81 | ACHE (0.36) | ALDH1A1KDM4ECYP3A4PDE4APDE4B | |
| SCHEMBL15172001 | 0.81 | ACHE (0.36) | ALDH1A1KDM4ECYP3A4PDE4APDE4B | |
| SCHEMBL25954061 | 0.79 | ELANE (0.46) | ALDH1A1CA1CA2ELANESMN1; SMN2 | |
| SCHEMBL164160 | 0.79 | ELANE (0.46) | ALDH1A1CA1CA2ELANESMN1; SMN2 | |
| SCHEMBL8131087 | 0.77 | KIF11 (0.44) | ALDH1A1CA1CA2CYP3A4SMN1; SMN2 | |
| SCHEMBL30730699 | 0.76 | CYP3A4 (0.47) | ALDH1A1KDM4EGAACYP1A1CYP1B1 | |
| SCHEMBL25489581 | 0.75 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAACYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-9273081-B2 | Method for in-situ formation of metathesis catalysts | ExxonMobil Product Solutions Company | 2016-03-01 | — | — | US | disclosed |
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | ExxonMobil Product Solutions Company | 2015-10-22 | — | — | US | disclosed |
| EP-2866936-A1 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8809563-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809563-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014004089-A1 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2533899-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-11-15 | — | — | US | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8237003-B2 | Metathesis catalyst and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2011100022-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100022-A2 | METATHESIS CATALYST AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885 |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885 |
| US-20120289729-A1 | Metathesis Catalyst and Process for Use Thereof | MGLL, FASN, FDFT1 | ALDH1A1 2327/4885KDM4E 1887/4885GAA 844/4885 |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | ALDH1A1 427/4885KDM4E 2393/4885GAA 4020/4885 |
| US-20110112349-A1 | Metathesis Catalyst and Process for Use Thereof | MGLL, FASN, MSMO1 | ALDH1A1 1338/4885KDM4E 2254/4885GAA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.